Loading
Oncotelic Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Trieu Vuong, was filed 10 Jul 2025.
Oncotelic Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Oncotelic Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. Oncotelic Therapeutics, Inc. has had no insider filing for more than a year; the last one goes back to 10 July 2025.
The full history, which starts in 2016, counts 30 purchases against no sales.
In the same sector, recent insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
39
Thresholds
n/a
Buy Volume
€110,731
30 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleVuong Trieu7 buys
Since the insiders bought
- -40.0%Entry US$0.05 · Close at T+365 US$0.03
- -45.0%Entry US$0.20 · Close at T+365 US$0.11
- -42.1%Entry US$0.19 · Close at T+365 US$0.11
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,804 of 26,289 companies
77.0
score / 100
Value57
Quality97
FCF yld-15%
Earn yld·
EV/EBITDA0.1x
ROE183%
Gross mgn·
Net mgn·
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.02
Analyst consensus
Income statement
RevenueUS$1.5M
EBITDAUS$361.5M24115% margin
Net incomeUS$249.3M98998.0% margin
Valuation
PER (trailing)0.0x
P/Book0.0x
Beta-0.19
Balance sheet & cash
Market capUS$9.2M
Total debtUS$13.9M
Free Cash Flow-US$1.4M
Debt / Equity5%
Profitability & ownership
ROE182.6%
ROA-1.6%
% insiders43.5%
% institutions0.0%
Last declaration on 10 July 2025
Declarations39 total
1 shares@ US$0.0050.0% of flowCommon StockSEC:0001641172-25-018620:1
Canonical exit: 7 Oct 2025 (T+90)
94,736 shares@ US$0.0050.5% of flowCommon StockSEC:0001641172-25-018620:2
Canonical exit: 6 Oct 2025 (T+90)
104,000 shares@ US$0.0050.6% of flowCommon StockSEC:0001641172-25-018620:0
Canonical exit: 8 Oct 2025 (T+90)
100,003 shares@ US$0.0283.1% of flowCommon StockSEC:0001493152-25-004486:1
Canonical exit: 30 Apr 2025 (T+90)
63,775 shares@ US$0.0282.0% of flowCommon StockSEC:0001493152-25-004486:2
Canonical exit: 1 May 2025 (T+90)
183,066 shares@ US$0.0286.8% of flowCommon StockSEC:0001493152-25-004486:0
Canonical exit: 29 Apr 2025 (T+90)
298,499 shares@ US$0.028911.4% of flowCommon StockSEC:0001493152-24-047762:0
Canonical exit: 20 Feb 2025 (T+90)
500,000 shares@ US$0.0212.4% of flowCommon StockSEC:0001493152-24-033939:0
Canonical exit: 21 Nov 2024 (T+90)
75,000 shares@ US$0.0262.0% of flowCommon StockSEC:0001493152-23-023015:1
Canonical exit: 26 Sept 2023 (T+90)
425,000 shares@ US$0.02111.3% of flowCommon StockSEC:0001493152-23-023015:0
Canonical exit: 27 Sept 2023 (T+90)
100,000 shares@ US$0.0263.3% of flowCommon StockSEC:0001493152-23-021800:0
Canonical exit: 14 Sept 2023 (T+90)
400,000 shares@ US$0.032616.6% of flowCommon StockSEC:0001493152-23-021563:0
Canonical exit: 12 Sept 2023 (T+90)
126,888 shares@ US$0.03415.6% of flowCommon StockSEC:0001493152-23-019557:0
Canonical exit: 24 Aug 2023 (T+90)
100,000 shares@ US$0.0455.6% of flowCommon StockSEC:0001493152-23-015195:0
Canonical exit: 31 Jul 2023 (T+90)
120,000 shares@ US$0.057.9% of flowCommon StockSEC:0001493152-22-034663:0
Canonical exit: 6 Mar 2023 (T+90)
70,000 shares@ US$0.087.5% of flowCommon StockSEC:0001493152-22-033681:0
Canonical exit: 20 Feb 2023 (T+90)
20,000 shares@ US$0.0681.9% of flowCommon StockSEC:0001493152-22-026963:0
Canonical exit: 25 Dec 2022 (T+90)
80,000 shares@ US$0.0829.1% of flowCommon StockSEC:0001493152-22-024234:0
Canonical exit: 23 Nov 2022 (T+90)
102,519 shares0Common StockSEC:0001493152-21-017102:1
259,302 shares0Common StockSEC:0001493152-21-017106:1
13,849,161 sharesCommon StockSEC:0001493152-21-017106:2
5,672,025 sharesCommon StockSEC:0001493152-21-017106:3
74,455,719 sharesCommon StockSEC:0001493152-21-017106:0
938,646 sharesCommon StockSEC:0001493152-21-017107:0
3,291,720 sharesCommon StockSEC:0001493152-21-017105:0
25 of 39 declarations
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. (OTLC) is a U.S.-based biopharmaceutical company currently quoted on the OTCQB market in the United States, and it fits the profile of a development-stage biotech whose valuation is driven by clinical, regulatory, and partnership milestones rather than mature product sales. For investors in the French-speaking market, the key takeaway is that Oncotelic positions itself around immuno-oncology, rare cancers, advanced drug-delivery technologies, and AI-enabled biomedical development. The company’s corporate headquarters are in Agoura Hills, California, United States. ([oncotelic.com](https://www.oncotelic.com/))
From a historical perspective, Oncotelic reflects a long-cycle biotech evolution and a continuation from its prior corporate identity associated with Mateon Therapeutics, as reflected in recent FDA correspondence referencing the merger/name-change history. This matters because the company’s story is less about rapid commercialization and more about assembling and repositioning a scientific asset base over time. Its development model combines in-house research, intellectual property, and joint-venture structures intended to finance and accelerate pipeline progress. ([fda.gov](https://www.fda.gov/media/182499/download))
Read moreShow less
The company’s lead program is OT-101, described by Oncotelic as its flagship immuno-oncology candidate. OT-101 is presented as a first-in-class anti-TGF-β RNA therapeutic with observed single-agent activity in relapsed/refractory cancer settings, and the company also states that it has activity against SARS-CoV-2. Beyond OT-101, Oncotelic highlights an oncology portfolio focused on rare pediatric cancers and other difficult-to-treat indications, alongside small-molecule and nanoparticle-based programs. Its website and recent updates also reference candidates and platforms such as CA4P, OXi4503, intranasal delivery concepts, and deciparticle-based development initiatives. ([oncotelic.com](https://www.oncotelic.com/))
Strategically, Oncotelic is trying to differentiate itself through a platform approach rather than a single-asset story. Management emphasizes AI-assisted biomarker discovery, translational analytics, and regulatory workflow enhancement, which suggests a broader ambition to shorten development timelines and improve target selection. That said, the company remains a small-cap biotech in a highly competitive field, where peers are numerous and differentiation depends on execution, data quality, and access to capital. It does not yet appear to be a commercial-stage pharmaceutical company; the investment case is still primarily pipeline-led. ([tmcnet.com](https://www.tmcnet.com/usubmit/-oncotelic-therapeutics-files-first-quarter-2026-financial-results-/2026/05/15/10383864.htm))
Geographically, the business is centered in the United States, with leadership and operations anchored in California, while its development and partnership footprint appears broader through clinical programs and joint ventures. Recent corporate updates indicate continued progress across OT-101 combination work, expansion of nanoparticle candidates, and further development of AI-enabled tools. In its FY2025 update, Oncotelic also highlighted a large non-cash uplift in the fair value of its JV interest and stated that operational costs tied to OT-101 and the nanoparticle platform are substantially covered by the joint venture, reducing direct funding pressure for the parent company. Management further mentioned ambitions tied to a potential Hong Kong IPO for the JV and a future uplisting to a national exchange. ([nasdaq.com](https://www.nasdaq.com/press-release/oncotelic-therapeutics-reports-fy-2025-results-highlighting-249m-net-income-and-jv))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
